Zobrazeno 1 - 10
of 14
pro vyhledávání: '"D. A. Chekini"'
Autor:
M. Yu. Fedyanin, F. V. Moiseenko, D. A. Chekini, V. A. Chubenko, A. S. Zhabina, L. A. Zagorskaya, M. M. Kramchaninov, S. A. Tjulandin, V. M. Moiseyenko
Publikováno v:
Медицинский совет, Vol 0, Iss 20, Pp 47-52 (2020)
Introduction. Trifluridine/Tipiracil (FTD/TPI) is a new chemotherapeutic drug approved in more than 60 countries for use in patients with metastatic colorectal cancer who have registered progression or intolerance to treatment with fluoropyrimidines,
Externí odkaz:
https://doaj.org/article/7960a21c1a0a4a80b8f80fc55c3111e3
Autor:
M. Yu. Fedyanin, E. M. Polyanskaya, I. A. Pokataev, A. A. Tryakin, O. V. Sekhina, D. A. Chekini, Kh.-Kh. M. Elsnukaeva, A. N. Polyakov, I. V. Sagaydak, V. D. Podluzhniy, V. A. Aliev, S. S. Gordeev, D. V. Kuzmichev, Z. Z. Mamedli, S. A. Tjulandin
Publikováno v:
Тазовая хирургия и онкология, Vol 9, Iss 4, Pp 21-31 (2019)
Objective: to assess the frequency of liver resections in patients with metastatic colon cancer and isolated non-resectable liver metastases receiving FOLFOXIRI. Materials and methods. In this single-center non-randomized prospective study, we assess
Externí odkaz:
https://doaj.org/article/96030a321071492db3b25dc0e696bf00
Autor:
M. Yu. Fedyanin, L. Yu. Vladimirova, N. A. Abramova, A. E. Storozhakova, I. L. Popova, N. M. Tikhanovskaya, E. A. Kalabanova, Е. G. Panina, A. I. Arzamastseva, E. G. Rybakov, L. V. Bolotina, T. V. Ustinova, А. А. Kachmazov, I. A. Pokataev, A. A. Tryakin, O. V. Sekhina, D. A. Chekini, Kh. Kh.-M. Elsnukaeva, D. V. Podluzhniy, S. A. Tjulandin, O. I. Kit
Publikováno v:
Тазовая хирургия и онкология, Vol 9, Iss 1, Pp 65-72 (2019)
Objective: to analyze the frequency of metastasectomy in general population of patients with RAS wild-type metastatic colorectal cancer who received chemotherapy and anti-EGFR monoclonal antibodiesMaterials and methods. This prospective, non-randomiz
Externí odkaz:
https://doaj.org/article/7ebf77bf1fc84cfd9d615caaea1ff937
Autor:
M. Yu. Fedyanin, Kh. Kh.-M. El’sunkaeva, I. A. Pokataev, A. A. Tryakin, A. A. Bulanov, O. V. Sekhina, D. A. Chekini, E. O. Ignatova, S. S. Gordeev, V. A. Aliev, D. V. Kuzmichev, Z. Z. Mamedli, M. V. Chernykh, V. V. Glebovskaya, S. I. Tkachev, N. A. Kozlov, S. A. Tjulandin
Publikováno v:
Тазовая хирургия и онкология, Vol 8, Iss 2, Pp 24-37 (2018)
Objective: to evaluate the prognostic value of clinical and pathomorphological stages in patients with rectal cancer after preoperative chemoradiotherapy and to assess the effectiveness of adjuvant chemotherapy in these patients.Materials and methods
Externí odkaz:
https://doaj.org/article/149181908ade4da9b4b2d3bbdd53a71c
Efficacy of first-line oxaliplatin-based chemotherapy regimens depending on the KRAS mutation status
Autor:
M. Yu. Fedyanin, Kh. Kh.-M. El’snukaeva, I. A. Pokataev, A. A. Tryakin, A. A. Bulanov, O. V. Sekhina, D. A. Chekini, E. O. Ignatova, S. S. Gordeev, M. D. Budurova, Z. Mamedli, D. V. Podluzhnyy, N. A. Kozlov, S. A. Tyulyandin
Publikováno v:
Тазовая хирургия и онкология, Vol 8, Iss 1, Pp 34-41 (2018)
Objective: to determine the efficacy of 2 oxaliplatin-based chemotherapy regimens (FOLFOX and XELOX) for metastatic colorectal cancer (CRC) depending on the KRAS mutation status and primary tumor location. Materials and methods. We performed retrospe
Externí odkaz:
https://doaj.org/article/f89e8956f46b4f8ea0792177ea22b12c
Autor:
N. M. Kutakov, D. A. Chekini
Publikováno v:
MD-Onco. 3:16-19
Currently, treatment of patients with early primary operable BRCA mutation-associated breast cancer requires integrative approach. A mutation in BRCA1/2 genes is a prognostically unfavorable factor increasing the risk of cancer of the contralateral b
Autor:
A. A. Filimonov, N. M. Kutakov, D. A. Chekini, E. M. Musaev, A. O. Akhov, A. G. Zhukov, O. L. Timofeeva, F. M. Abbasbeyli, Yu. E. Ryabukhina, P. A. Zeynalova, A. A. Fedenko, E. K. Ibragimov
Publikováno v:
MD-Onco. 2:56-62
Osteosarcomas are rare tumors with aggressive biology. It is important to refer such patients to a high-volume center, where an accurate diagnosis and optimal treatment are more likely to be performed. In contrast to Ewing's sarcoma, conventional ost
Autor:
A. O. Rasulov, J. M. Madyarov, A. E. Kulikov, Z. R. Rasulov, L. A. Shestakova, D. A. Chekini, E. K. Ibragimov, E. N. Puchkova, Yu. E. Lvova, R. A. Rasulov
Publikováno v:
MD-Onco. 2:21-27
Immunotherapy has improved the results of treatment of patients with metastatic colorectal cancer. According to literature, the most cancericidal effect revealed in a microsatellite instability high (MSI-H) tumors. In our case, PD-1/PD-L1/PD-L2 inhib
Publikováno v:
MD-Onco. 2:36-42
Currently, use of CDK4/6 inhibitors in combination with hormone therapy is approved for treatment of patients with advanced or metastatic breast cancer positive for estrogen and progesterone receptors and negative for human epidermal growth factor re
Autor:
Yu. E. Ryabukhina, A. A. Fedenko, P. A. Zeynalova, O. L. Timofeeva, F. M. Abbasbeyli, D. A. Chekini, A. M. Mudunov, A. F. Batsev, O. V. Sinitsyna, A. G. Zhukov, L. A. Shestakova, G. F. Allakhverdieva, I. N. Yurichev
Publikováno v:
MD-Onco. 2:14-23
Alveolar rhabdomyosarcoma (ARMS) is an aggressive primitive tumor with limited differentiation of rhabdomyoblasts. Primarily, it occurs in children and teens under 15 years of age in the head and neck region (in 40 % of cases). In patients older than